EHA 2017 | New aims and next steps for adult ALL induction therapy
Dieter Hoelzer
• 22 Jun 2017
Dieter Hoelzer, MD, PhD from the Onkologikum Frankfurt am Museumsufer, Frankfurt, Germany talks about aiming higher in the treatment of adult acute lymphoblastic leukemia (ALL) patients at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain. Prof. Hoelzer shares encouraging results of a 90% complete remission rate after induction therapy with the next step being to achieve the same results with less toxicity. Asparaginase, a therapy proven to be successful in children is his main focus. He discusses the aim of treatment, molecular remission and minimal residual disease (MRD) status which is important for determining outcome and future therapy.
